NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free INCY Stock Alerts $56.43 -0.62 (-1.09%) (As of 12:40 PM ET) Add Compare Share Share Today's Range$56.37▼$57.3850-Day Range$51.18▼$60.7952-Week Range$50.27▼$67.36Volume1.33 million shsAverage Volume1.88 million shsMarket Capitalization$12.67 billionP/E Ratio17.10Dividend YieldN/APrice Target$74.93 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Incyte alerts: Email Address Incyte MarketRank™ Stock AnalysisAnalyst RatingHold2.47 Rating ScoreUpside/Downside32.2% Upside$74.93 Price TargetShort InterestBearish4.29% of Shares Sold ShortDividend StrengthN/ASustainability-2.66Upright™ Environmental ScoreNews Sentiment0.43Based on 25 Articles This WeekInsider TradingN/AProj. Earnings Growth26.84%From $3.54 to $4.49 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.85 out of 5 starsMedical Sector37th out of 929 stocksCommercial Physical Research Industry2nd out of 12 stocks 4.2 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 8 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageIncyte has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.29% of the outstanding shares of Incyte have been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Incyte has recently increased by 16.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 38.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Janus-associated kinase (JAK) inhibitors", "Ponatinib", and "Tafasitamab" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -2.66. Previous Next 1.9 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Incyte this week, compared to 8 articles on an average week.Search InterestOnly 8 people have searched for INCY on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have not sold or bought any company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 26.84% in the coming year, from $3.54 to $4.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 17.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 17.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 186.11.Price to Earnings Growth RatioIncyte has a PEG Ratio of 1.76. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressThe most important AI company you've never heard ofBecause this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.Get the full story on this secret AI company poised for massive growth About Incyte Stock (NASDAQ:INCY)Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More INCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCY Stock News HeadlinesMay 16 at 8:29 AM | markets.businessinsider.comIncyte’s Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold RatingMay 15 at 6:40 PM | msn.comIncyte’s stock rallies 9% after company says to buy back $1.67 billion of its own stock in Dutch auction tenderMay 15 at 1:39 PM | wsj.comStocks to Watch Monday: GameStop, AMC, Squarespace, IncyteMay 15 at 1:39 PM | forbes.comHow Does Incyte Stock’s Decline During The 2022 Inflation Shock Compare With The 2008 Crash?May 14 at 5:00 PM | businesswire.comIncyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressMay 14 at 3:39 PM | finance.yahoo.comCompany News For May 14, 2024May 14 at 5:26 AM | marketwatch.comStock Market Today: Dow snaps 8-day winnning streakMay 14 at 5:26 AM | finance.yahoo.comHeard on the Street Monday Recap: Hello KittyMay 14 at 12:26 AM | benzinga.comGameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On MondayMay 14 at 12:26 AM | marketwatch.comIncyte Shares Rally on $2 Billion Buyback PlansMay 14 at 12:26 AM | msn.comIncyte Stock Marks Biggest Jump in 7 Years on ‘Dutch Auction’ Buyback Plan. How It Works.May 13 at 7:25 PM | marketwatch.comStock Market Today: Dow trades higher as S&P 500 nudges toward record territoryMay 13 at 6:00 PM | investopedia.comS&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback PlanMay 13 at 8:20 AM | marketwatch.comIncyte Sets $2 Billion Stock BuybackMay 13 at 8:20 AM | msn.comIncyte to buy back $1.67 billion of its own stock in Dutch auction tenderMay 13 at 7:00 AM | businesswire.comIncyte Announces Intention to Buy Back up to $2.0 Billion of its Common StockMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 8, 2024 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) Receives Average Recommendation of "Hold" from BrokeragesMay 4, 2024 | finance.yahoo.comIncyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 2, 2024 | businesswire.comIncyte to Present at Upcoming Investor ConferenceMay 1, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Incyte (INCY)April 30, 2024 | markets.businessinsider.comIncyte Corporation Q1 Profit Increases, but misses estimatesApril 30, 2024 | msn.comIncyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75MApril 30, 2024 | reuters.comIncyte misses quarterly profit on weak sales of lead drugApril 30, 2024 | finance.yahoo.comIncyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in ...See More Headlines Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/16/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,524Year Founded1991Price Target and Rating Average Stock Price Target$74.93 High Stock Price Target$93.00 Low Stock Price Target$52.00 Potential Upside/Downside+31.3%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio17.29 Forward P/E Ratio16.12 P/E Growth1.76Net Income$597.60 million Net Margins19.78% Pretax Margin27.03% Return on Equity12.83% Return on Assets9.80% Debt Debt-to-Equity Ratio0.01 Current Ratio3.47 Quick Ratio3.43 Sales & Book Value Annual Sales$3.70 billion Price / Sales3.47 Cash Flow$2.41 per share Price / Cash Flow23.66 Book Value$24.02 per share Price / Book2.38Miscellaneous Outstanding Shares224,540,000Free Float185,246,000Market Cap$12.81 billion OptionableOptionable Beta0.69 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Herve Hoppenot (Age 64)CEO & Chairman Comp: $2.89MMs. Christiana Stamoulis MBA (Age 53)Executive VP & CFO Comp: $1.16MDr. Barry P. Flannelly M.B.A. (Age 66)Pharm.D., Executive VP & GM of North America Comp: $996.28kDr. Steven H. Stein M.D. (Age 57)Executive VP & Chief Medical Officer Comp: $1.22MDr. Pablo J. Cagnoni M.D. (Age 61)Ph.D., President and Head of Research & Development Mr. Thomas Tray (Age 46)VP of Finance, Chief Accounting Officer & Controller Mr. Michael James Morrissey (Age 60)Executive VP & Head of Global Technical Operations Sheila A. Denton (Age 58)Executive VP, General Counsel & Corporate Secretary Ms. Pamela M. Murphy (Age 73)Vice President of Investor Relations & Corporate Communications Ms. Paula J. Swain (Age 66)Executive Vice President of Human Resources Comp: $611.92kMore ExecutivesKey CompetitorsMedpaceNASDAQ:MEDPCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHPPDNASDAQ:PPDExelixisNASDAQ:EXELView All CompetitorsInsiders & InstitutionsAshford Capital Management Inc.Sold 23,924 shares on 5/16/2024Ownership: 0.155%Caxton Associates LPSold 19,636 shares on 5/16/2024Ownership: 0.013%Janus Henderson Group PLCSold 7,895 shares on 5/16/2024Ownership: 0.009%Bayesian Capital Management LPBought 18,255 shares on 5/16/2024Ownership: 0.008%Kennedy Capital Management LLCBought 8,124 shares on 5/16/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions INCY Stock Analysis - Frequently Asked Questions Should I buy or sell Incyte stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. View INCY analyst ratings or view top-rated stocks. What is Incyte's stock price target for 2024? 17 brokerages have issued 1 year price objectives for Incyte's stock. Their INCY share price targets range from $52.00 to $93.00. On average, they expect the company's share price to reach $74.93 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price. View analysts price targets for INCY or view top-rated stocks among Wall Street analysts. How have INCY shares performed in 2024? Incyte's stock was trading at $62.79 at the start of the year. Since then, INCY stock has decreased by 9.7% and is now trading at $56.68. View the best growth stocks for 2024 here. When is Incyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our INCY earnings forecast. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, February, 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by $0.09. The biopharmaceutical company earned $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Incyte had a trailing twelve-month return on equity of 12.83% and a net margin of 19.78%. The firm's revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.44 earnings per share. Read the conference call transcript. What ETFs hold Incyte's stock? ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), iShares Genomics Immunology and Healthcare ETF (IDNA), BTD Capital Fund (DIP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), Bushido Capital US Equity ETF (SMRI), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and ASYMshares ASYMmetric S&P 500 ETF (ASPY). What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA). Who are Incyte's major shareholders? Incyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (16.11%), Vanguard Group Inc. (10.12%), Acadian Asset Management LLC (1.24%), LSV Asset Management (1.23%), Jacobs Levy Equity Management Inc. (1.12%) and Bellevue Group AG (0.96%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INCY) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.